0001209191-24-000425.txt : 20240103 0001209191-24-000425.hdr.sgml : 20240103 20240103164744 ACCESSION NUMBER: 0001209191-24-000425 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240101 FILED AS OF DATE: 20240103 DATE AS OF CHANGE: 20240103 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Balthaser Kevin CENTRAL INDEX KEY: 0001957554 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37581 FILM NUMBER: 24507540 MAIL ADDRESS: STREET 1: C/O ACLARIS THERAPEUTICS, INC. STREET 2: 701 LEE ROAD, SUITE 103 CITY: WAYNE STATE: PA ZIP: 19087 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aclaris Therapeutics, Inc. CENTRAL INDEX KEY: 0001557746 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 460571712 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 701 LEE ROAD STREET 2: SUITE 103 CITY: WAYNE STATE: PA ZIP: 19087 BUSINESS PHONE: 484-324-7933 MAIL ADDRESS: STREET 1: 701 LEE ROAD STREET 2: SUITE 103 CITY: WAYNE STATE: PA ZIP: 19087 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2024-01-01 0 0001557746 Aclaris Therapeutics, Inc. ACRS 0001957554 Balthaser Kevin C/O ACLARIS THERAPEUTICS, INC. 701 LEE ROAD, SUITE 103 WAYNE PA 19087 0 1 0 0 Chief Financial Officer 0 Common Stock 2024-01-01 4 M 0 7500 A 22961 D Common Stock 2024-01-01 4 F 0 2536 1.05 D 20425 D Restricted Stock Units 2024-01-01 4 M 0 7500 0.00 D Common Stock 7500 22500 D Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4. On February 1, 2023, the Reporting Person was granted 30,000 restricted stock units. The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of January 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date. /s/ Mark Ballantyne, Attorney-in-Fact 2024-01-03